Aclarion, Inc. (NASDAQ:ACON) Short Interest Up 19.8% in January

Aclarion, Inc. (NASDAQ:ACON) saw a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 178,163 shares, an increase of 19.8% from the January 15th total of 148,674 shares. Based on an average trading volume of 159,610 shares, the short-interest ratio is currently 1.1 days. Approximately 21.0% of the company’s stock are sold short. Approximately 21.0% of the company’s stock are sold short. Based on an average trading volume of 159,610 shares, the short-interest ratio is currently 1.1 days.

Aclarion Price Performance

Shares of NASDAQ:ACON opened at $2.58 on Tuesday. Aclarion has a 1 year low of $2.34 and a 1 year high of $229.50. The company has a market cap of $2.19 million, a P/E ratio of -0.17 and a beta of 1.44. The stock’s fifty day moving average price is $4.51 and its 200-day moving average price is $6.36.

Analyst Upgrades and Downgrades

ACON has been the subject of several recent research reports. Wall Street Zen lowered shares of Aclarion from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.